Sitemap
June 08, 2024 Articles
Filter by Available Specialty
- ‘Unprecedented level of fibrosis improvement’ through 96 weeks with efruxifermin for MASH
- Dana-Farber Cancer Institute names surgeon-in-chief
- Novel, benign nail finding linked to syndrome that increases risk for certain cancers
- Rifaximin ‘cannot be recommended’ as antibiotic prophylaxis for severe cirrhosis, ascites
- Stryker announces definitive agreement to acquire Artelon
- Survodutide improves MASH without worsening of fibrosis in more than 64% at 48 weeks
- VIDEO: Heart in Diabetes unveils new guidance for diabetes, cardiorenal and metabolic diseases
- VIDEO: Silverstone device enhances retinal imaging